Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Abraxane Neoadjuvant Therapy for Breast Cancer
NCT00397761Phase 3Withdrawn
- Sponsor
- MedStar Health Research Institute
- Start
- Jul 2006
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nab-paclitaxel and capecitabine in breast cancer, sponsored by MedStar Health Research Institute. Primary endpoint: Pathological Complete Response Rate. Planned start Jul 2006; status: withdrawn.
02
Drugs
nab-paclitaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00397761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397761.